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Abstract
Loss-of-function mutations in APOPT1, a gene exclusively found in
higher eukaryotes, cause a characteristic type of cavitating
leukoencephalopathy associated with mitochondrial cytochrome c
oxidase (COX) deficiency. Although the genetic association of
APOPT1 pathogenic variants with isolated COX defects is now
clear, the biochemical link between APOPT1 function and COX has
remained elusive. We investigated the molecular role of APOPT1
using different approaches. First, we generated an Apopt1 knock-
out mouse model which shows impaired motor skills, e.g.,
decreased motor coordination and endurance, associated with
reduced COX activity and levels in multiple tissues. In addition, by
achieving stable expression of wild-type APOPT1 in control and
patient-derived cultured cells we ruled out a role of this protein in
apoptosis and established instead that this protein is necessary for
proper COX assembly and function. On the other hand, APOPT1
steady-state levels were shown to be controlled by the ubiquitina-
tion–proteasome system (UPS). Conversely, in conditions of
increased oxidative stress, APOPT1 is stabilized, increasing its
mature intramitochondrial form and thereby protecting COX from
oxidatively induced degradation.
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Introduction
Isolated mitochondrial cytochrome c oxidase (COX) deficiency
(OMIM #220110) is one of the most common biochemical presenta-
tions in individuals suffering from mitochondrial disease. This
enzymatic deficit is associated with diverse clinical presentations,
and the phenotypic heterogeneity is mirrored by a large number of
mutations reported in more than twenty different genes associated
with COX and its assembly (Rak et al, 2016).
COX or complex IV (cIV) is the terminal component of the
mitochondrial respiratory chain (MRC), catalyzing the oxidation of
cytochrome c and the reduction of molecular oxygen to water. The
energy liberated by this redox reaction sustains the transfer of two
protons and four charges across the inner membrane to help
sustain the proton electrochemical potential gradient exploited in
ATP synthesis, operated by complex V or mitochondrial ATP
synthase. Three of the fourteen COX structural subunits, MT-CO1,
MT-CO2, and MT-CO3, are encoded in the mitochondrial genome
(mtDNA), and mutations in all three have been associated with
COX deficiency (Rak et al, 2016). The other subunits are nuclear-
encoded, and some of them have tissue-specific isoforms, such as
COX6A2 and COX7A1 in cardiac and skeletal muscle and COX6B2
in testis, or are expressed in certain physiological conditions such
as COX4I2 during hypoxia (Sinkler et al, 2017). Mutations in the
nuclear-encoded COX structural subunits are much rarer (Massa
et al, 2008; Shteyer et al, 2009; Indrieri et al, 2012; Pitceathly
et al, 2013; Tamiya et al, 2014; Hallmann et al, 2016; Abu-Libdeh
et al, 2017; Baertling et al, 2017). Nevertheless, a large number of
COX deficiency cases arise from mutations in nuclear genes encod-
ing proteins that are involved in cytochrome c oxidase biogenesis
(Rak et al, 2016; Timon-Gomez et al, 2018). Information about
these COX assembly factors obtained by studying Saccharomyces
cerevisiae has been very useful in the identification of human
orthologs (Tzagoloff & Dieckmann, 1990; Barrientos, 2003; Zee &
Glerum, 2006; Soto et al, 2012). However, although the absence of
these assembly factors leads to impaired formation of fully assem-
bled COX and COX deficiency, their molecular role is still
unknown in many cases. Furthermore, it is now clear that there
are animal-specific genes encoding COX assembly factors that are
not found in yeast (Weraarpachai et al, 2009; Martinez Lyons
et al, 2016; Vidoni et al, 2017; Lorenzi et al, 2018).
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Loss-of-function mutations in APOPT1, a gene only found in
metazoans, have been described as the cause of mitochondrial
encephalopathy, characterized by cavitating leukodystrophy with a
distinctive MRI pattern, in seven individuals from six different
families (Melchionda et al, 2014; Sharma et al, 2018). Although
the genetic association of APOPT1 pathogenic variants with
isolated COX deficiency is well established, the biochemical link
between APOPT1 and cIV remains unclear (Melchionda et al,
2014). Here, we have characterized the role of APOPT1 in COX
maturation in mouse tissues and human cultured cells. We took
advantage of the availability of immortalized patient-derived skin
fibroblasts (Melchionda et al, 2014) and also generated an Apopt1
knockout mouse model, which displays isolated COX deficiency
associated with impaired motor endurance and coordination.
APOPT1-less mouse tissues and human fibroblasts showed low
steady-state levels of COX subunits and accumulation of early COX
assembly intermediates containing the MT-CO1 subunit. In addition,
we observed a faster turnover of newly synthesized mtDNA-
encoded COX subunits in APOPT1-null cells, likely before their
incorporation into the COX complex. Oxidative stress enhanced the
degradation of these mtDNA-encoded COX subunits, which was
prevented by APOPT1. Moreover, the APOPT1 precursor was
actively degraded in the cytoplasm by the proteasome, whereas
elevated ROS levels stabilized the protein and increased its import
into mitochondria. Altogether, these observations indicate a role for
APOPT1 in protecting COX assembly from oxidation-induced degra-
dation. While in normal conditions most of the APOPT1 precursor is
rapidly destroyed in the cytoplasm by the ubiquitin–proteasome
system (UPS), overproduction of mitochondrial ROS stabilizes the
protein and increases its mitochondrial import and conversion into
the mature, active form.
Results
Generation of the Apopt1 knockout mouse model
CRISPR/Cas9 was used for genomic editing of Apopt1 to generate
a knockout mouse model. To this end, RNA encoding the
Streptococcus pyogenes Cas9 (SpCas9) plus a customized guide
RNA (gRNA) targeting exon 2 were introduced into FVB/NJ 1-day
zygotes. The edited embryos were transferred into pseudo-preg-
nant females and genotyping of the resulting pups identified four
founder mice (F0), each carrying several indel modifications. This
chimerism could be due to the fact that Cas9 can stay active after
several mitotic divisions and that the non-homologous end-joining
(NHEJ) DNA repair pathway, which is activated by the CRISPR/
Cas 9 editing, is a random process, resulting in multiple muta-
tions. To ensure germline transmission and allow allele segrega-
tion, the founder mice were bred with wild-type FVB/NJ mice.
Genetic analysis of F1 mice confirmed the presence of heterozy-
gous frameshift indels. After screening of several pups, an individ-
ual was selected carrying a substitution of one A with a TG
doublet in Apopt1 exon 2 (c.188delAinsTG, mRNA sequence
GenBank NM_026511), which generates a frameshift resulting in a
p.Asp55Valfs*20 truncated protein (Fig 1A and B). Crossing of
heterozygous mice produced Mendelian ratios of the three possible
genotypes, including 25% of mutated homozygous mice
Apopt1/. Apopt1 protein levels could not be analyzed due to
the lack of a specific signal for the mouse protein, despite assess-
ing two commercially available and two custom-made antibodies.
However, the Apopt1 mRNA levels skeletal muscle and liver were
25 and 50% in Apopt1/ compared to those found in the corre-
sponding tissues of wild-type Apopt1+/+ individuals. The amount
of Apopt1 mRNA in the heterozygous mice (Apopt1+/) was
between those of the +/+ and / genotypes (Fig 1C).
Apopt1/ mice display reduced motor performance
Body weight was not significantly different at 3, 6, or 12 months of
age between Apopt1/ and wild-type mice for both genders
(Fig 2A), and no major metabolic effects were observed among any
of these groups (Appendix Fig S1A–G). Apopt1/ mice did not
display feet clasping (Appendix Fig S1J), and the pole-test results,
measuring general proprioception, were normal (Appendix Fig
S1H). Memory and spatial learning, evaluated by the Y-maze test
and measured as percentage of arms alternation, was not affected at
any age (Appendix Fig S1I). However, the total number of arm
entries was significantly lower in Apopt1/ mice of 6 and
12 months of age (Fig 2D) showing age-related impairment of
exploratory behavior. To further explore this, spontaneous move-
ments were monitored in 3- and 12-month-old mice, and a strong
reduction of horizontal activity was found only in the older knock-
out animals, in accordance with the Y-maze test results (Fig 2E).
Moreover, both male and female Apopt1/ mice performed signifi-
cantly worse in the treadmill and rotarod tests at 3 months of age,
reflecting impaired motor endurance and coordination, respectively
(Fig 2B and C). In order to assess the progression of the phenotype,
these tests were repeated with 6- and 12-month-old Apopt1/ mice.
However, no further change was observed in their neuromuscular
performance as they aged (Fig 2B and C).
APOPT1/ mice display general COX enzymatic and
assembly defects
Skeletal muscle histochemical investigations showed normal fiber
morphology in Apopt1/ animals, with no ragged red fibers
(Fig 3A). However, COX staining was clearly reduced, whereas
succinate dehydrogenase (SDH) staining was normal (Fig 3B).
Lower COX staining without any evident histopathological alteration
was also observed in the brain and kidney (Fig 3B).
COX enzymatic activity in tissue homogenates confirmed the
significantly reduced activity, by 40–60% of controls, in skeletal
muscle, kidney, heart, brain, and liver of 3-month-old Apopt1/
mice compared with Apopt1+/+ or Apopt1+/ controls, which
showed indistinguishable activities (Fig 3C). One-year-old skeletal
muscle, liver and brain still showed significant COX deficits
compared with age-matched wild-type animals (Fig 3C). The activi-
ties of other respiratory chain complexes and of citrate synthase
were the same as controls, except for the liver, where complex I and
III activities were also slightly reduced in the Apopt1/ samples
(Appendix Fig S2A).
The steady-state levels of COX structural subunits were
decreased in Apopt1/ liver, skeletal muscle, and brain (Fig 3D, as
well as in cultured MEFs (Appendix Fig S2B). Interestingly, the late
(MT-CO3 and COX6B) and intermediate (MT-CO2 and COX5B)
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Figure 1. Generation of the Apopt1 knockout mouse model.
A Strategy employed for the targeted disruption of mouse chromosome 12 Apopt1 coding exon 2 by CRISPR/Cas9. The mutation selected for the characterization of the
mouse model produced an indel (c.188delAinsTG) resulting in a frameshift and truncated protein (p.Asp55Valfs*20).
B Chromatograms generated by Sanger sequencing of Apopt1/ (KO) and Apopt1+/+ (WT) genomic DNA highlighting the mutated position in comparison with the
wild-type sequence.
C Relative mRNA expression of Apopt1 normalized to the expression of GAPDH in skeletal muscle and liver of wild-type, heterozygous, and knockout mice of 3 months
of age. Data are presented as mean  SEM (n = 6 mice per genotype). The asterisks represent the significance levels calculated by two-way ANOVA with Sidak’s
multiple comparisons test: muscle—***P = 0.0001 (WT vs. KO), *P = 0.0310 (WT vs. het), *P = 0.0395 (het vs. KO), liver—**P = 0.0022 (WT vs. KO), *P = 0.0101
(WT vs. het).
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assembly subunits as well as MT-CO1 were decreased to a greater
extent than the subunits that assemble earlier (COX4 and COX5A;
Fig 3D), suggesting that loss of Apopt1 is most detrimental to the
intermediate steps of the COX assembly pathway (Vidoni et al,
2017).
The amounts of fully assembled complex IV were significantly
lower in Apopt1/ skeletal muscle, as shown in one-dimension
(1D) blue-native gel electrophoresis (BNGE), Western blot, and
immunodetection (Fig 3E) and in cultured MEFs (Appendix Fig
S2B). Accumulation of subcomplexes containing the MT-CO1
module (Vidoni et al, 2017), also known as “MITRAC” for mito-
chondrial translation regulation assembly intermediate of cyto-
chrome c oxidase (Mick et al, 2012), was observed by second
dimension (2D) BNGE (Fig 3F). The assembly defect was specific
for COX as other respiratory complexes were unaffected.
APOPT1 is present in a low molecular weight complex in the
mitochondrial inner membrane
Human APOPT1 cDNA was amplified from two cell lines: HeLa and
HEK 293T. Two different isoforms were detected after cloning and
sequencing of the PCR fragments. The first isoform is the transcript
containing five coding exons, annotated as APOPT1-201 in Ensembl
(www.ensembl.org) with Transcript ID ENST00000409074.6,
encoding the full-length protein (Uniprot Q96IL0). The second
isoform is APOPT1-203, lacking exon 3 and with Transcript ID
ENST00000458117.5, encoding a truncated protein (Uniprot
H7C2Z1).
Both isoforms were cloned starting from each of the two putative
ATG start codons present in the open reading frame: M1 and M14.
These four different cDNAs were fused to GFP in the C terminus
and expressed in three different human cell lines (see below). In
parallel, a C-terminal HA tag was added to the four cDNA sequences
and transfected into 143B osteosarcoma cells. Despite being targeted
to mitochondria, the expression levels evaluated by immunofluores-
cence of APOPT1-203-M1GFP and APOPT1-203-M14GFP were lower
than the full-length APOPT1-201 version in all the tested cell lines
(Appendix Fig S3A), and the HA-tagged versions were undetectable
by Western blot and immunofluorescence (Appendix Fig S3B and
C), which suggests that the protein is not folding correctly and is
rapidly degraded. This idea was reinforced by the fact that deletion
of APOPT1 exon 3 causes the pathological phenotype of COX defi-
ciency and encephalopathy (Melchionda et al, 2014; Sharma et al,
2018). Both APOPT1-201-M1 and APOPT1-201-M14 tagged with HA
and GFP produce the same size proteins (Appendix Fig S3), being
both targeted to mitochondria, leading to the conclusion that the
starting methionine is M14, as was proposed in our original report
(Melchionda et al, 2014). The tagged APOPT1-201-M1 constructs
will be termed APOPT1GFP and APOPT1HA, respectively, from now
on.
APOPT1GFP protein was detected upon transduction in HeLa,
143B cells, and immortalized control skin fibroblasts, whereas
APOPT1HA expression in 143B cells was much lower, indicating that
the intrinsic instability of the protein, as previously reported by
Melchionda et al, was corrected in the GFP chimeric variant.
However, contrary to the original report on the identification of
APOPT1 (Yasuda et al, 2006), we observed no induction of cell
death when APOPT1GFP or APOPT1HA was overexpressed
(Appendix Fig S4A–C). Therefore, we have no evidence that
APOPT1 acts as an apoptogenic factor when overexpressed in
human cells. Both APOPT1GFP and APOPT1HA were used to
immunodetect the presence of the protein in subcellular fractions.
APOPT1 is synthesized as a 22.9-kDa precursor including a mito-
chondrial targeting sequence of 26 amino acids which is cleaved off
when imported (Melchionda et al, 2014), producing a mature
protein with a predicted molecular mass of 20.1 kDa. Immortalized
fibroblasts derived from patients S2 and S6, carrying homozygous
p.Arg79* and heterozygous p.Arg79*/p.Glu124del truncating muta-
tions, respectively (Melchionda et al, 2014), showed a drastically
reduced signal of the band corresponding to the size of mature
APOPT1 (20 kDa), when immunodetected with antibodies raised
against human APOPT1, which are able to recognize the native
protein in human cell lysates (Appendix Fig S5A). The presence or
absence of the endogenous precursor protein was impossible to
determine as an intense unspecific band of the same electrophoretic
mobility as pre-APOPT1 cross-reacts with the anti-APOPT1 antibody
(Appendix Fig S5A). On the other hand, the precursor of both tagged
versions, APOPT1HA of 24 kDa and APOPT1GFP, with a predicted
mass of 51 kDa but with an observed migration of 35–40 kDa, were
immunovisualized with the specific antibodies against the C-term-
inal tags (Fig 4A–C and Appendix Fig S5B).
To determine endogenous and overexpressed tagged APOPT1
localization, we isolated mitochondria from osteosarcoma 143B
cells expressing APOPT1HA and APOPT1GFP and from HEK293
human cells. We first tested the association of APOPT1 with the
soluble or membrane mitochondrial fractions. Virtually all the
endogenous as well as the HA- and GFP-tagged APOPT1 species
were associated with the mitochondrial membranes, by a rela-
tively loose binding, since carbonate extraction was able to release
a large proportion of the protein into the supernatant (Fig 4A and
▸Figure 2. Clinical phenotype characterization of the Apopt1 knockout mice.A Body weight measured in female and male animals at 3, 6, and 12 months of age. Data are presented as mean  SEM (n = 5 per group).
B Distance run by the tested female and male mice on the treadmill at 3 and 12 months of age. Data are presented as mean  SEM (n = 6 per group). The asterisks
represent the significance levels calculated by two-way ANOVA with Sidak’s multiple comparisons test: females—****P < 0.0001 (3 months), ***P = 0.0004
(12 months), males—****P < 0.0001 (3 months), **P = 0.0019 (12 months).
C Time in seconds spent by the female and male mice on the Rotarod cylinders before falling at different ages. Data are presented as mean  SEM (n = 5 per group).
The asterisks represent the significance levels calculated by two-way ANOVA with Sidak’s multiple comparisons test: females—**P = 0.0059 (3 months), **P = 0.0083
(6 months), *P = 0.0391 (12 months), males—**P = 0.0069 (12 months).
D Number of entries in each arm of the Y-maze performed at different ages. Data are presented as mean  SEM (n = 10 per group). The asterisks represent the
significance levels calculated by two-way ANOVA with Sidak’s multiple comparisons test: ****P < 0.0001.
E Total spontaneous horizontal and vertical movements of 12-month-old mice measured in an activity cage. Data are presented as mean  SEM (n = 6 per group). The
asterisks represent the significance levels calculated by two-way ANOVA with Sidak’s multiple comparisons test: ****P < 0.0001 (horizontal).
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Appendix Fig S5B). Then, we studied the sub-mitochondrial local-
ization in mitoplasts produced by treating mitochondria by either
increasing concentrations of digitonin, or hypotonic shock. The
mitoplasts were then exposed to trypsin and the integrity and
amount of APOPT1 were compared to those of markers specific to
the four different mitochondrial compartments: matrix, inner
membrane (IM), intermembrane space (IMS), and outer membrane
(OM). APOPT1HA showed a trypsin digestion pattern intermediate
to AIF or AK2 (IMS markers) and those of COX4 (IM with its N-
terminal domain facing the matrix) and ACO2 a soluble matrix
protein (Fig 4B and Appendix Fig S5C). This observation was
inconclusive to establish whether APOPT1 was facing the matrix
or protruding to the IMS. The question was readdressed biochemi-
cally by generating mitoplasts using hypotonic shock, incubating
the mitochondria in a buffer containing 5 mM sucrose and testing
APOPT1HA sensitivity to trypsin compared with different markers.
In addition, supernatants were collected after centrifuging the
mitochondria in either isotonic or hypotonic buffers, to confirm
that hypotonic treatment was associated with the release of IMS
proteins. No APOPT1HA was released to the supernatant after
hypotonic shock. We then challenged the APOPT1HA found in the
pellet with trypsin and found that APOPT1HA sensitivity to the
protease was much more similar to that of COX, an IM protein
facing the matrix, than that of SCO2, an IM protein facing the IMS
(Fig 4C). The difference between the results with digitonin and
those with hypotonic shock was likely due to the disruption of IM
by high concentrations of digitonin, whereas the hypotonic shock
maintained IM integrity. To further validate these results, fluores-
cence super-resolution microscopy on 143B cells expressing
APOPT1GFP showed that GFP fluorescence was contained within
the IM, decorated by DS-RED fluorescent protein targeted to IM by
the COX8A MTS, and displayed significant co-localization with
MitoTracker, staining the IM and the matrix (IM + M), and matrix
(M) markers (Fig 4D and Appendix Fig S6). Taken together, these
observations indicate that APOPT1 is a protein associated with the
inner membrane, with its C terminus located in the matrix.
In addition, Western blot of 2D-BNGE of samples solubilized
with the two non-denaturing detergents, n-dodecyl-b-D-maltoside
(DDM) and digitonin, revealed that APOPT1HA and APOPT1GFP
migrate to the bottom of the gel (Appendix Fig S5D). This suggests
that both versions of APOPT1 are not stably interacting in a high
molecular weight complex, including COX assembly intermediates
containing MT-CO1 or MT-CO2.
Stable expression of wild-type APOPT1 complements the COX
defect in patient-derived fibroblasts
Similar to what was observed in the Apopt1/ mouse tissues, two
skin fibroblast cell lines, derived from two independent patients
carrying pathological mutations in APOPT1 (S2 and S6), show low
steady-state levels of COX subunits, reduced levels of fully assem-
bled COX, and decreased COX activity (Fig 5A–C). Both mutated cell
lines were transduced with APOPT1HA and although the protein was
always detectable, its amount decreased with time (Fig 5A). Conse-
quently, the complementation of the enzymatic COX defect was
partial, especially for S2 (Fig 5A). On the other hand, expression of
APOPT1GFP was much more robust and stable, and therefore, trans-
duced S2 and S6 patient cells showed full recovery of COX assembly
and COX enzymatic activity, which were around 50% of the control
in the non-transduced (naı¨ve) and GFP alone transduced cells
(Fig 5B and C).
APOPT1 participates in the intermediate steps of COX
assembly and its absence accelerates the degradation of
mtDNA-encoded subunits
The assembly defect in S2 and S6 patient fibroblasts not only leads
to an accumulation of subassemblies of the MT-CO1 module (as
was also observed in mouse tissues) but it also affects the late COX
intermediate containing subunits COX4 and COX5A plus the MT-
CO1 and MT-CO2 modules, also known as “S3” (Nijtmans et al,
1998; Vidoni et al, 2017), which is markedly reduced in cells lacking
APOPT1 (Fig 5C and D). These COX assembly defects observed in
non-transfected or mock-transfected patient-derived fibroblasts were
reverted by expression of wild-type APOPT1GFP (Fig 5C and D).
We excluded the possibility that the COX defect in APOPT1-less
cells and tissues could be due to a role of APOPT1 in transcription
or translation of COX subunits, as no changes were detected in
mtDNA-encoded MT-CO1 and MT-CO2 or nuclear-encoded COX4
and COX6B mRNA levels (Appendix Fig S7). Furthermore, the
synthesis of 35S labeled mtDNA-encoded proteins was comparable
in the mock-transfected patient cells (expressing only GFP) and the
controls, i.e., patient cells transfected with APOPT1GFP and wild-
type immortalized fibroblasts (Fig 5E). In contrast, when the stabil-
ity of the protein products was evaluated at different chase times,
the amounts of labeled MT-CO2/MT-CO3 in the non-complemented
S2 and S6 cells were significantly lower than in the controls after
▸Figure 3. Morphological, biochemical, and structural analysis in mouse tissues.A Representative hematoxylin and eosin staining of skeletal muscle in 3-month-old individuals.
B Histochemical reaction specific to COX and SDH in skeletal muscle, cerebellar cortex, and kidney of the same individuals.
C COX (CIV) enzymatic activity normalized to the activity of citrate synthase (CS) in five animals per genotype as indicated at 3 and 12 months of age. Data are
presented as mean  SEM (n = 6 per group). The asterisks represent the significance levels calculated by two-way ANOVA with Sidak’s multiple comparisons test:
Three months: Muscle (SM)—***P = 0.0001 (WT vs. KO), kidney (K)—***P = 0.0002 (WT vs. KO), heart (H)—***P = 0.0001 (WT vs. KO), brain (B) and liver (L)—
****P < 0.0001 (WT vs. KO). Twelve months: SM and L—****P < 0.0001, B—***P = 0.0008 (WT vs. KO).
D Western blot analysis of SDS–PAGE of total lysates from liver, skeletal muscle, and brain from the indicated genotypes, each lane showing the results for one animal.
The graph shows the densitometric quantification of the signals obtained in the liver. Data are presented as mean  SEM (n = 2 WT; n = 2 het; n = 3 KO). The
asterisks represent the significance levels calculated by two-way ANOVA with Sidak’s multiple comparisons: ***P = 0.0002 and ****P < 0.0001 (WT vs. KO).
E Western blot analysis of 1D-BNGE of mitochondria from skeletal muscle from the indicated genotypes, each lane showing the results from one animal.
F Western blot analysis of 2D-BNGE of mitochondria from skeletal muscle from one individual of the indicated genotype. Red arrows indicate the accumulation of COX
assembly intermediates in Apopt1/ samples.
Source data are available online for this figure.
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only 3.5 h of culture in “cold” medium, whereas MT-CO1 protein
levels were clearly decreased after 6.5 h (Fig 5E). The differences
became even more significant at subsequent time points, indicating
accelerated degradation of mtDNA-encoded COX subunits in the
absence of APOPT1.
APOPT1 cytoplasmic levels are regulated by the ubiquitination–
proteasome system (UPS)
Our original report showed that transfected APOPT1HA was stabi-
lized following treatment with the proteasome inhibitor MG132
(Melchionda et al, 2014). Further treatments of the newly trans-
duced 143B cells, expressing higher amounts of APOPT1HA, with
MG132 showed an increase in the precursor protein and a corre-
sponding decrease of the mature, cleaved form (Fig 6A). In
addition, higher, HA-immunoreactive bands appeared under protea-
somal inhibition, which corresponded to ubiquitinated forms of
APOPT1, as confirmed by immunoblotting for ubiquitin of immuno-
precipitated APOPT1HA (Fig 6B).
Oxidative stress induces APOPT1 stabilization and import into
mitochondria where it protects COX from degradation
Our preliminary observations showed that APOPT1 was stabilized
when cells were exposed to H2O2 (Melchionda et al, 2014). This
phenomenon was confirmed in 143B cells overexpressing
APOPT1HA and APOPT1GFP after a few minutes of exposure to
100 lM H2O2 (Fig 6C). The rapidity of this response and the consid-
eration that expression of the recombinant protein was under the
control of a constitutive exogenous promoter, suggested that this
effect was due to a post-translational stabilization of the protein
rather than to its increased synthesis. In support of this conclusion,
APOPT1 stabilization was not a consequence of proteasome inacti-
vation by oxidative stress (Livnat-Levanon et al, 2014; Segref et al,
2014) as we did not find an increase in general ubiquitination or in
HSP70 levels under exposure to 100 lM H2O2 (Fig 6C and
Appendix Fig S8). Furthermore, pharmacological proteasome inhibi-
tion led to the preferential accumulation of the APOPT1 precursor,
whereas H2O2 treatment increased the amounts of the mature
species, suggesting either enhanced import or intramitochondrial
stabilization, or both. APOPT1 tagged with HA or with GFP
increased 5–10 min after treatment with H2O2 which continued for
up to 6 h, when APOPT1 returned to initial levels (Fig 6C). Other
mitochondrial proteins did not vary under these conditions
(Fig 6C).
To test whether this effect could be due to ROS selectively gener-
ated within mitochondria, we used MitoParaquat (MitoPQ) which is
specifically imported into the organelle and generates superoxide
(O2 ) only in the mitochondrial matrix (Fig 6C; Robb et al, 2015).
Superoxide can then be dismutated by MnSOD to H2O2, which can
exit the mitochondria (Brand, 2016; Sies, 2017). Treatment with
5 lM MitoPQ in 143B cells overexpressing APOPT1HA and
APOPT1GFP also promoted the rapid stabilization of both APOPT1
tagged proteins (Fig 6C).
We then treated S6 patient-derived APOPT1-deficient immortal-
ized fibroblasts with 5 lM MitoPQ and analyzed the effect on
protein levels for up to 20 h. Similar to what we observed in 143B
cells, APOPT1GFP levels increased around 4-fold in the comple-
mented fibroblasts after 10 min from the start of MitoPQ treatment,
reaching a maximum of 8-fold after 30 min to eventually decrease
to pre-treatment levels after 20 h of incubation (Fig 7A and B). The
addition of MitoPQ to the culture medium of APOPT1-deficient cells
resulted in a gradual decrease of the levels of MT-CO2 and MT-CO1,
being the reduction in the latter statistically significant after 20 h of
MitoPQ exposure (Fig 7A, C and D). Conversely, wild-type immor-
talized fibroblasts and APOPT1GFP complemented patient cells
showed no decrease in the amounts of MT-CO1 and MT-CO2, or
even a slight increase, following MitoPQ treatment. The levels of
subunit COX5A of complex IV as well as of some subunits
of complexes I and III were unaffected by the presence or absence
of APOPT1 (Fig 7A).
Discussion
The results shown here establish a clear link between APOPT1 and
COX biogenesis. In our previous report, we tried to validate this
association by knocking down APOPT1 expression by RNAi in dif-
ferent human cells (Melchionda et al, 2014). Although APOPT1
mRNA levels were significantly reduced in the RNAi interfered cell
lines, we were unable to demonstrate a clear COX defect, possibly
because the residual normal APOPT1 transcript levels could still be
▸Figure 4. Mitochondrial sub-localization of APOPT1.A Western blot of SDS–PAGE of different fractions from 143B cells expressing APOPT1HA. Tot: total lysate. Cyto: post-mitochondrial fraction (cytoplasm). Mt: isolated
mitochondria. Mt sol: soluble mitochondrial fraction. Mt memb: mitochondrial membranes. CO23 pellet: pellet after carbonate extraction with 0.1 M Na2CO3, pH 10.5
for 30 min. CO23 sol: soluble fraction after the carbonate extraction.
B Western blot of SDS–PAGE of mitochondria used for protease protection assay after digitonin treatment. The experiment was carried out in isolated mitochondria
from 143B cells expressing APOPT1HA exposed to increasing amounts of digitonin (expressed in lg) and 50 lg/ml trypsin. Complete solubilization with 1% Triton X-
100 was used as a control of protease sensitivity. TOM20: Translocase of the outer membrane (OM) 20 kDa. ACO2: aconitase 2 (mitochondrial isoform). AIF: apoptosis-
inducing factor. AK2: adenylate kinase 2. OM: outer mitochondrial membrane. IM: inner mitochondrial membrane. IMS: intermembrane space.
C Western blot of SDS–PAGE of mitochondria used for protease protection assay after hypotonic shock. The experiment was carried out in isolated mitochondria from
143B cells expressing APOPT1HA incubated either in isotonic (Iso) or in hypotonic buffers for 5 min (Hypo 50) or 15 min (Hypo 150) and 50 lg/ml trypsin. Complete
solubilization with 1% Triton X-100 was used as a control of protease sensitivity.
D N-SIM super-resolution micrographs showing 0.8 lm Maximum Intensity Projection (0.15 lm for each Z-stack) of 143B cells expressing APOPT1GFP shown in green,
specific markers for each mitochondrial compartment: TOMM20 (OM), COX8A (IM), MitoTracker (IM + M), and matrix-target (mScarlet) shown in red. Scale bar: 5 lm.
The graph shows Pearson’s coefficient in co-localized volume of different sub-compartment combinations with APOPT1GFP. Data show mean  SEM (n = 5). One-way
ANOVA (*P = 0.0298 and **P = 0.0076) was employed for the statistical analysis.
Source data are available online for this figure.
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translated to give a sufficient amount of protein to achieve normal
COX assembly. In support of this possibility stands, the observation
that all the mutations so far reported in APOPT1 patients carried
either homozygous or compound heterozygous loss-of-function
mutations which prevented the synthesis of a full-length protein. In
addition, acute shRNA treatment in control immortalized fibroblasts
induced cell death (Melchionda et al, 2014), a phenomenon for
which we still have no explanation since APOPT1-null patient
fibroblasts show normal growth in standard culture conditions.
Contrariwise, APOPT1 was originally described as an inducer of cell
death by apoptosis (Yasuda et al, 2006; Sun et al, 2008). However,
we did not observe any cell death or growth arrest when overex-
pressing APOPT1 in three different human cell lines, including HeLa
transduced with APOPT1 tagged with a C-terminal GFP, as in the
original report (Yasuda et al, 2006).
The genetic knockout mouse model of Apopt1 showed global
COX deficiency with reduced enzymatic activity, low steady-state
levels of structural subunits and defective assembly in all the tested
tissues. The in vivo mouse model was also exploited to evaluate the
impact of Apopt1 deletion on metabolic, neurological, and motor
phenotypes. Apopt1/ mice show significantly impaired motor
coordination and endurance, indicative of neurological and muscu-
lar involvement in the clinical phenotype, thus confirming APOPT1
as a disease gene. In humans, APOPT1 deficiency is associated with
a very characteristic cavitating leukoencephalopathy, which may
prompt to specific analysis of the APOPT1 gene (Sharma et al,
2018).
The transfection and transduction systems previously used did
not allow the stable expression of the HA-tagged APOPT1 protein in
human fibroblasts, despite being highly overexpressed at the mRNA
level, thus preventing the functional characterization of APOPT1
(Melchionda et al, 2014). By optimizing the transduction and
expression systems with different viral vectors and recombinant
constructs, we have achieved stable translation of wild-type human
APOPT1HA and APOPT1GFP in different human tumor cell lines and
immortalized fibroblasts. This fact, plus the development of
polyclonal antibodies recognizing the endogenous human protein,
enabled us to reliably determine APOPT1 mitochondrial and
◀ Figure 5. Defective COX assembly and accumulation of assembly intermediates in APOPT1-less human cells.A APOPT1HA was expressed in S6 and S2 immortalized fibroblasts as shown by the Western blot immunovisualization. The expression levels were tested at different
days after transduction. The graph on the right shows the activities of CIV normalized to CS in three biological replicates per cell line. Data are presented as
mean  SEM (n = 3). The asterisks represent the significance levels calculated by two-way ANOVA with Tukey’s multiple comparisons test: **P = 0.0030 (S6 naïve vs.
S6 APOPT1HA), *P = 0.0165 (S6 EV vs. S6 APOPT1HA).
B APOPT1GFP was expressed in S6 and S2 immortalized fibroblasts as shown by the Western blot immunovisualization. The graph on the right shows the activities of
CIV normalized to CS in four biological replicates per cell line. Data are presented as mean  SEM (n = 4). The asterisks represent the significance levels calculated
by two-way ANOVA with Tukey’s multiple comparisons test: **P = 0.0066 (S6 naïve vs. S6 APOPT1GFP), ***P = 0.0006 (S6 GFP vs. S6 APOPT1GFP), *P = 0.0169 (S2 naïve
vs. S2 APOPT1GFP), ***P = 0.0008 (S2 GFP vs. S2 APOPT1GFP).
C Western blot analysis of 1D-BNGE of mitoplasts extracted from the indicated cell lines. Fully assembled COX migrating at 200 kDa was immunovisualized with
antibodies recognizing MT-CO1 and MT-CO2. The presence of the assembly intermediates “MITRAC” and “S3” was also detected (arrows).
D Western blot analysis of 2D-BNGE of mitoplasts extracted from the indicated cell lines. Fully assembled COX was immunovisualized with antibodies recognizing MT-
CO1 and MT-CO2. The presence of the assembly intermediates “MITRAC” and “S3” was also detected (arrows). Anti-GFP immunodetection revealed the presence of
the low molecular weight APOPT1GFP complex in the complemented cells expressing the tagged protein.
E L-[35S]-Methionine pulse-chase labeling of mtDNA-encoded proteins. After a 2-h exposure with the radioactive label (pulse), cells were cultured in cold medium
for the indicated chase times. The graphs show the densitometric quantification of the bands corresponding to MT-CO1 (left graph) and MT-CO2 + MT-CO3
(right graph) normalized to the ATP6 band over the indicated time points. Graphs represent the values of three biological replicas for each cell line. Data are
presented as mean  SEM (n = 4 for controls, n = 2 for S2/S6/S2 APOPT1GFP/S6 APOPT1GFP). The symbols represent the significance levels calculated by two-way
ANOVA with Tukey’s multiple comparisons test: MT-CO1—3.5 h: *P = 0.0202 (controls vs. S2), ††P = 0.0039 (controls vs. S6); 6.5 h: *P = 0.0118 (controls vs. S2),
††P = 0.0011 (controls vs. S6), §P = 0.0163 (S6 vs. S6 APOPT1GFP); 20 h: ***P = 0.0002 (controls vs. S2), ††††P < 0.0001 (controls vs. S6), #P = 0.0343 (S2 vs. S2
APOPT1GFP), §§§P = 0.0007 (S6 vs. S6 APOPT1GFP). MT-CO2/MT-CO3—3.5 h: †††P = 0.0003 (controls vs. S6), §P = 0.0194 (S6 vs. S6 APOPT1GFP); 6.5 h: §P = 0.0375 (S6
vs. S6 APOPT1GFP); 20 h: **P = 0.0013 (controls vs. S2), ††††P < 0.0001 (controls vs. S6), #P = 0.0234 (S2 vs. S2 APOPT1GFP), §§§§P < 0.0001 (S6 vs. S6 APOPT1GFP).
Data information: C1 and C2: control immortalized fibroblasts. EV: Cells transduced with the empty vector. Naïve: Non-transduced immortalized fibroblasts. GFP: Cells
transduced with a recombinant GFP expression vector. Tubulin, SDHB, and SDHA were used as loading controls in the different experiments as indicated.
Source data are available online for this figure.
▸Figure 6. Effects of proteasome inhibition and ROS overproduction on APOPT1 stability.A Western blot analysis of SDS–PAGE of MGM132-treated 143B APOPT1HA cells. The graph represents the densitometric quantification of the signals for the precursor
and mature protein.
B The upper part of the panel (Input) shows Western blot analyses of APOPT1HA in the MGM132-treated cells. Note the appearance of higher molecular weight bands
upon longer exposure in the samples treated with the proteasome inhibitor. The bottom part of the panel (Purified fractions) shows the analysis of fractions from the
same cells immunoprecipitated with anti-HA. Note that the higher molecular weight species are cross-reacting with both anti-HA and anti-ubiquitin.
C Western blot analysis of SDS–PAGE of total lysates from 143B cells overexpressing tagged APOPT1 (as indicated) and exposed to 100 lM H2O2, as illustrated by the
scheme (H2O2 treatment), for the indicated times. The graphs represent the densitometric quantification of the tagged APOPT1 signal at each time point. The graph
inset shows that the increase of APOPT1 occurs in the first minutes after the exposure to H2O2.
D Western blot analysis of SDS–PAGE of total lysates from 143B cells overexpressing tagged APOPT1 (as indicated) and exposed to 5 lM MitoParaquat (MitoPQ), as
illustrated by the scheme (MitoPQ treatment), for the indicated times. The graphs represent the densitometric quantification of the tagged APOPT1 signal at each
time point. The graph inset shows that the increase of APOPT1 occurs in the first minutes after the exposure to MitoPQ.
Source data are available online for this figure.
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sub-mitochondrial localization as a protein associated to the inner
membrane and facing the IMS. In addition, transduction of
APOPT1HA and APOPT1GFP in immortalized fibroblasts derived from
two unrelated patients, S2 and S6 (Melchionda et al, 2014), rescued
the enzymatic and assembly COX defect. Taken together, the
evidence collected from the in vivo and cell models establishes
unequivocally the involvement of APOPT1 in COX biogenesis and
excludes a role of this protein in apoptosis, at least in the cells and
tissues considered in our study. Therefore, we propose that its name
be changed to cytochrome c oxidase assembly factor (COA) 8,
adding to the collection of already known COX assembly factors
named COA 1–7.
The assembly defect shown by all the APOPT1-null models
analyzed, i.e., Apopt1/ tissues as well as patient-derived immortal-
ized fibroblasts, involves the global down-regulation of COX with an
accumulation of subcomplexes including early assembly subunits
(COX4 and COX5A) and the MT-CO1 module (Vidoni et al, 2017;
largely coincidental with the MITRAC complex (Mick et al, 2012)).
Consistent with this observation, COX4, COX5A, and MITRAC
steady-state levels were less reduced than those of the MT-CO2 and
MT-CO3 modules, involved in later steps of COX assembly (Vidoni
et al, 2017; Timon-Gomez et al, 2018). Moreover, the “S3”
subassembly, containing the MT-CO1 and MT-CO2 modules
together, is markedly reduced in the patient-derived cells and mouse
tissues. Thus, APOPT1/COA8 must play a role in joining or stabiliz-
ing the MT-CO2 module to COX4-COX5A and MT-CO1. Absence of
APOPT1/COA8 does not affect the synthesis of any of the mtDNA-
encoded COX subunits. However, their stability is severely compro-
mised, being most probably actively degraded due to impaired incor-
poration into the nascent complex. This same phenomenon has been
consistently observed when different COX assembly factors, such as
SCO1, COX20, CMC1, or COX18, are mutated or absent in human
cells, determining the stalling in the assembly of the MT-CO1 module
(Leary et al, 2009; Bourens et al, 2014; Bourens & Barrientos, 2017a,
b). Accordingly, it has been shown that COX-deficient S. cerevisiae
strains showing high sensitivity to hydrogen peroxide and an accu-
mulation of subassemblies containing hemylated Cox1 (Khal-
imonchuk et al, 2007, Veniamin et al, 2011) display a faster turnover
of unassembled COX subunits, which is mediated by the ATPase
Afg1 (Khalimonchuk et al, 2007). Interestingly, LACE1, the human
orthologue of Afg1, has also been shown to be involved in the degra-
dation of nuclear-encoded COX subunits (Cesnekova et al, 2016).
Therefore, these lines of evidence strongly suggest that there is a
regulatory mechanism of COX assembly that links the accumulation
of MT-CO1 containing subassemblies with faster degradation of
unassembled COX subunits. In the case of APOPT1 deficiency,
neither the human cultured cells nor the mouse tissues showed
increased H2O2 production in non-induced conditions (results not
shown); however, when the patient-derived fibroblasts were oxida-
tively challenged, they showed a significant increase in ROS produc-
tion compared to the controls (Melchionda et al, 2014), which
argues in favor of a “pro-oxidant state” in the absence of APOPT1. In
addition, these same APOPT1-null cells showed further reduction in
COX levels when oxidants were added to the culture medium. The
presence of APOPT1 in control cells (both complemented patient and
control fibroblasts) protected COX from this damage. These observa-
tions underscore the association of APOPT1 function with COX
assembly and stabilization of the enzyme as well as with the protec-
tion of the nascent enzyme from oxidative damage, which leads to
degradation of its structural components.
Concerning the regulation of APOPT1/COA8, the results
presented here indicated active ubiquitination and proteasome-
mediated degradation of the APOPT1 precursor in the cytoplasm.
UPS-mediated degradation of mitochondria-targeted proteins has
been proposed as a regulatory mechanism to prevent the accumula-
tion of these precursor proteins in the cytoplasm and consequent
cellular stress (Bragoszewski et al, 2013; Wrobel et al, 2015). In
addition, the UPS is involved in several other processes controlling
mitochondrial fitness, such as fission and fusion, PINK1 and
PARKIN-mediated mitophagy and regulation of the OM and IMS
mitochondrial proteome (reviewed in Bragoszewski et al, 2017).
However, this kind of mechanism has never been described in asso-
ciation with COX biogenesis. In addition, in short-term and mild
oxidative stress conditions, APOPT1/COA8 import inside mitochon-
dria is enhanced. This phenomenon cannot be attributed to direct
proteasome inhibition by H2O2 (Livnat-Levanon et al, 2014; Segref
et al, 2014) as we did not observe signs of accumulation of ubiquiti-
nated proteins or increased heat-shock protein response. Moreover,
pharmacological inhibition of the proteasome produced the prefer-
ential accumulation of APOPT1 precursor and not of the mature
protein, indicating that a significant proportion of newly synthesized
APOPT1 is normally ubiquitinated and degraded by the proteasome
in the cytoplasm before mitochondrial import. On the other hand,
oxidative stress induced by direct addition of H2O2 in the cell culture
medium or via MitoPQ increased the amount of the mature protein,
suggesting that H2O2 outside mitochondria and/or ROS produced
within the organelle could be the signal to activate or unblock
APOPT1/COA8 import, as well and to stabilize it inside mitochon-
dria. It is well known that H2O2 can generate regulatory signals by
oxidative modification of key Cys residues in responsive proteins
(Hurd et al, 2005; Murphy, 2009; Hamanaka & Chandel, 2010;
Brand, 2016; van Leeuwen et al, 2017; Sies, 2017). Human and
◀ Figure 7. Effects of MitoPQ treatment in the absence or presence of APOPT1.A Western blot analysis of SDS–PAGE of different mitochondrial proteins in total lysates from the indicated cell lines treated with 5 lM MitoPQ at the indicated times.
UT: untreated cells.
B Densitometric quantification of APOPT1GFP signal during the treatment in two biological replicas. Data are presented as mean  SEM (n = 2).
C Densitometric quantification of MT-CO1 signal in the non-complemented APOPT1-less cells (S6 GFP) vs. the complemented cells (S6 APOPT1GFP). Three biological
replicas and two technical replicates were carried out for each cell line. The signals in UT S6 APOPT1 were considered 100%. Data are presented as mean  SEM
(n = 3). The levels of MT-CO1 were significantly lower in the S6 GFP patient cells after 20 h of MitoPQ treatment compared to the untreated cells (*P = 0.0202,
two-tailed unpaired Student’s t-test).
D Densitometric quantification of MT-CO2 signal in the non-complemented APOPT1-less cells (S6 GFP) vs. the complemented cells (S6 APOPT1GFP). Three biological
replicas and two technical replicates were carried out for each cell line. The signals in UT S6 APOPT1 were considered 100%. Data are presented as mean  SEM (n = 3).
Source data are available online for this figure.
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mouse APOPT1 have Cys residues eleven amino acids upstream and
nineteen amino acids downstream of the predicted MTS cleavage
site, which are conserved in mammalian species. In fact, oxidative
folding mediated by Cys residues is a very well-studied mechanism
in yeast, necessary for the import and regulation of IMS proteins
through the MIA (mitochondrial IMS import and assembly) pathway
(Wasilewski et al, 2017), including some COX structural subunits
and assembly factors (Khalimonchuk & Winge, 2008). Oxidative
regulation of the import of mitochondrial inner membrane or matrix
proteins has not been described before and further experimental
demonstration will be needed to test the possibility of a H2O2-
mediated APOPT1/COA8 structural change through oxidative modi-
fication of its Cys residues to favor its import inside mitochondria.
In summary, here we have conclusively demonstrated that
genetic ablation of APOPT1 is directly related to COX deficiency and
mitochondrial disease. Moreover, we propose a mechanism of
modulation of COX assembly that is mediated by regulating the
levels of APOPT1/COA8, first in the cytoplasm by degrading it
through the UPS and secondly by ROS, which stimulates its import
into mitochondria to promote COX assembly at intermediate steps
by stabilizing and/or protecting the COX subassemblies from oxida-
tive damage. Further experimental work will be undertaken to
understand the specific ROS-mediated molecular mechanism by
which APOPT1 is imported inside mitochondria and what proteins
bind and collaborate with it.
Materials and Methods
Generation of APOPT1/ mice
The gRNA is composed of a “scaffold” sequence, necessary for the
binding of the Cas, and a user-defined 20-nucleotide sequence,
known as “spacer”, that determines the genomic region to be
targeted. The “spacer” was designed using the next web tool:
http://crispr.mit.edu/ and was targeted to the exon 2 of the mouse
Apopt1 gene (GenBank ID: 68020). The sequence with the highest
quality score, meaning perfect homology with the target with an
NGG sequence at the 30 end (PAM sequence, necessary for the bind-
ing and activation of the Cas9) and no off-targets in any other gene,
was: 50-CTGGGGGGCCTATCCAATCATGG-30. The plasmid pSpCas9
(BB)-PX330 (Addgene plasmid # 42230) was used as a template to
amplify by PCR the gRNA construct (“spacer” + “scaffold”)
preceded by a T3 promoter to allow subsequent in vitro transcrip-
tion. The product amplified was then cloned into the pCR2.1 TOPO
TA cloning kit (Invitrogen), and the resulting plasmid was linear-
ized by digestion with the restriction enzyme EcoRI and transcribed
in vitro (Riboprobe system-T3, Promega). The commercial plasmid
encoding the SpCas9 (Addgene plasmid # 48625) was also linearized
by digestion with SphI and transcribed in vitro (Riboprobe system-
T3, Promega). After RNA purification of the gRNA and Cas9, the
sequences were sent for microinjection into fertilized FVB/NJ one-
cell embryos (Core Facility for Conditional Mutagenesis, Milan).
Animal work
All procedures were conducted under the 1986 UK Animals (Scien-
tific Procedures) Act and approved by Home Office license (PPL:
7538 and P6C97520A) and local ethical review. The mice were
kept on FVB/NJ background, and wild-type littermates were used
as controls. The animals were maintained in a controlled environ-
ment within the animal care facility in the Phenomics Laboratory,
Forvie Site, Cambridge Biomedical Campus, Cambridge, UK.
Animals of both gender at 3, 6, and 12 months of age, as indicated
in the legends of the figures, were used for the various phenotype
analyses.
Histopathological analysis
Mice were euthanized by cervical dislocation, and organs were
quickly dissected, frozen by immersing in isopentane cooled with
liquid nitrogen, and stored in cryovials in a 80°C freezer. Tissues
were then sectioned in a cryostat, placed in slides. The slides were
then stained for COX and SDH, as described (Sciacco & Bonilla, 1996).
For histological and immunohistochemical analyses, mice were anes-
thetized with an overdose of pentobarbital and perfused with PBS
followed by 10% neutral buffer formalin (NBF). Hematoxylin–eosin
and Nissl staining were performed by standard methods.
Behavioral tests
Mice were monitored weekly to examine body condition, weight
loss, and general health. Neurological, motor, and metabolic pheno-
type was further evaluated with the set of tests described below.
Hindlimb clasping
Mice were grasped from the base of the tail, lifted clear of all
surrounding objects and their hindlimb position observed for 10 s.
Normal position was defined as hindlimbs splayed outward, away
from the abdomen, and abnormal as one or both hindlimbs
retracted toward the abdomen.
Comprehensive laboratory animal monitoring system (CLAMS)
Apopt1/ mice and control littermates were individually placed in
the CLAMSTM system of metabolic cages and monitored over a 36-h
period. Data were collected every 10-min. The parameters analyzed
were: VO2 (volume of oxygen consumed, ml/kg/h), VCO2 (volume
of carbon dioxide produced, ml/kg/h), RER (respiratory exchange
ratio), heat (kcal/h), XYZ total activity, ambulatory movements,
and rear movements.
Treadmill
Mice were forced to run to exhaustion (defined as > 10 falls/min) in
a treadmill apparatus (Columbus Instruments, Columbus, OH). One
trial for two consecutive days was conducted prior to testing to
allow the mice enough time to acclimatize. On the test day, the
treadmill was set to an angle of inclination of 10°. The speed was
initially set at 11 m/min for 3 min, and it was increased 0.3 m/min
every 3 min up to a maximum speed of 75 m/min.
Rotarod
A rotarod apparatus (Ugo Basile, Italy) was used to assess motor
performance and coordination. One trial for two consecutive days
was conducted prior to testing to allow the mice enough time to
acclimatize. On the test day, three trials were completed setting the
rod to accelerate from 2 to 40 rpm in 300 s. The latency to fall was
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recorded. Mice were returned to their home cage during the inter-
trial interval of 15–20 min.
Y-maze spontaneous alternation
The test was conducted in a large Y-shaped maze with three equal
arms of 40 cm length, 8 cm width, and 15 cm height, attached at
120° angle from each other. Mice were placed at the center of the
maze and allowed to freely explore the three arms for 5 min. No
acclimatization was required as this test evaluates the willingness of
mice to explore new environments. The sequence of arm entries
was manually recorded and then the total number of entries plotted
and the percentage of alternation calculated as:
% alternation ¼ actual alternation
maximum alternation
 
 100
Actual alternation = number of correct alternations (defined as
entry into all three arms consecutively); Maximum alterna-
tion = total number of entries minus two
Pole test
Mice were placed head-upward on the top of a vertical rough-
surfaced pole (diameter 5 mm; height 50 cm) and the time to orien-
tate downward and descend it was recorded with a maximum dura-
tion of 60 s. Three trials for two consecutive days were conducted
prior to testing to allow the mice enough time to acclimatize. On the
test day, animals received three trials and the time to descend the
pole was recorded.
Activity cage
Mice were individually placed in the center of an activity cage (Ugo
Basile, Italy) and left 5 min to freely explore before commencing the
test to allow them enough time to acclimatize. After that, horizontal
and vertical movements were recorded at intervals of 1 min for
30 min.
Mitochondrial extraction and subfractionation
Mitochondrial isolation from mouse tissues and cultured cells was
performed as described (Fernandez-Vizarra et al, 2006; Ferna´ndez-
Vizarra et al, 2010).
In order to separate the soluble and membrane fractions, freshly
isolated mitochondria were sonicated three times and then centrifuged
at 100,000 × g for 30 min at 4°C to separate the supernatant containing
the soluble proteins and the membrane-associated proteins in pellet
(Ghezzi et al, 2009). To split the peripherally bound from the integral
membrane proteins, the pellets obtained in the previous centrifugation
step were resuspended in a buffer containing 0.1 M Na2CO3, pH 10.5,
0.25 M sucrose and 0.2 mM EDTA; incubated for 30 min on ice and
then centrifuged at 100,000 × g for 30 min at 4°C, to separate the pellet
the from the supernatant containing the loosely bound membrane
proteins (Satoh et al, 2003).
For sub-mitochondrial localization, mitochondria were isolated
as described above, split in 0.5 mg aliquots and treated with
increasing digitonin amounts (from 75 to 1,200 lg) and 50 lg/ml
trypsin at room temperature for 30 min. To assess mitochondria
integrity, one sample was treated with protease but no digitonin.
As a control of protein digestion, one sample was treated with
trypsin in the presence of 1% Triton X-100. For the hypotonic
shock, mitochondria were incubated in either isotonic buffer
(320 mM sucrose, 10 mM Tris–HCl pH 7.4, 1 mM EDTA), hypo-
tonic buffer (5 mM sucrose, 10 mM Tris–HCl pH 7.4, 1 mM
EDTA), for either 5 or 15 min, or completely solubilized with 1%
Triton X-100. One-half of each sample was then treated with
50 lg/ml trypsin at room temperature for 30 min. Afterward, mito-
chondria from trypsin-treated and untreated samples were centri-
fuged at 9,000 × g for 10 min at 4°C, and the supernatant was
separated from the pellets. The pellets were washed twice with
isotonic buffer and finally solubilized with 1% SDS for SDS–PAGE
and WB analysis.
Enzymatic assays
The activities of the respiratory chain enzymes and citrate synthase
(CS) were measured in mitochondria-enriched tissue samples and in
digitonin solubilized cell samples by spectrophotometry in a 96-well
plate reader as described previously (Tiranti et al, 1995; Kirby et al,
2007), with slight modifications.
Human samples
The primary and immortalized cultured fibroblasts were derived
from patients S2 and S6, reported in Melchionda et al (2014) and
were provided by the cellular BioBank of Telethon Italy located at
the Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
Informed consent was obtained at the time of biopsy collection
under local ethical committee approval. All the procedures involv-
ing human samples were performed under the principles set out in
the WMA Declaration of Helsinki and the Department of Health and
Human Services Belmont Report.
Cell culture
Human HeLa, 143B osteosarcoma cells, and primary and immortal-
ized skin fibroblasts were grown in high-glucose DMEM plus Gluta-
max and sodium pyruvate supplemented with 10% fetal bovine
serum (FBS), 1× penicillin and streptomycin (all from Gibco-Life
Technologies), and 50 lg/ml uridine (Sigma) in humidified atmo-
sphere at 37°C and 5% CO2. Selective media were prepared adding
1 lg/ml puromycin or 100 lg/ml hygromycin (both from Invivo-
Gen).
Oxidative stress in cell cultures
143B cells overexpressing APOPT1HA or APOPT1GFP were treated
with 100 lM H2O2 for 5 and 10 min and for 3, 6, 10, and 20 h. Same
cell lines plus wild-type, mutated, and APOPT1GFP complemented
fibroblasts were treated with 5 lM MitoParaquat for 10 and 30 min
and for 3, 6, and 20 h. Samples were then lysed in RIPA buffer
(50 mM Tris pH 7.4, 0.1% SDS, 1% NP-40, 0.5% Na deoxycholate,
150 mM NaCl) with the addition of protease inhibitors (cOmpleteTM
Mini EDTA-free Protease Inhibitor Cocktail, 100 mM NEM and
100 mM IAA). Lysates were centrifuged at 16,900 × g for 20 min;
supernatants were mixed with loading buffer and separated by SDS–
PAGE prior to immunoblotting.
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Proteasome inhibition and ubiquitination assay
143B empty vector (EV), APOPT1HA cells were treated with 10 lM
MG132 for 2 or 6 h. For the immunoprecipitation of APOPT1HA to
assess for ubiquitination, 1 × 107 143B EV or 143B APOPT1HA cells
were treated with or without MG132 for 2 h and lysed in RIPA
buffer (50 mM Tris pH 7.4, 0.1% SDS, 1% NP-40, 0.5% Na deoxy-
cholate, 150 mM NaCl) with the addition of protease inhibitors
(cOmpleteTM Mini EDTA-free Protease Inhibitor Cocktail, 100 mM
NEM, and 100 mM IAA). Lysates were centrifuged at 16,900 × g for
10 min. The supernatant was centrifuged at 135,800 × g for 1 h,
before samples were pre-cleared using sepharose CL4B for (1 h,
4°C). Samples were then incubated with 10 ll EZviewTM Red Anti-
HA beads (Sigma-Aldrich) overnight at 4°C. Resins were washed
five times with RIPA buffer, and the bound proteins were eluted
using 40 ll 100 lg/ml HA peptide (Sigma-Aldrich; in 0.5% NP-40
with protease inhibitors) for 1 h at 4°C. Protein samples in loading
buffer were heated at 75°C for 10 min and separated by SDS–PAGE
prior to immunoblotting.
Cell growth
Growth curves were assessed using an Incucyte ZOOM or an Incu-
cyte HD instrument (Essen Bioscience) using an algorithm to calcu-
late cell confluency based on microscope imaging of the plates.
Images were taken every 2 h for a total period of 4 days.
Cloning of APOPT1 cDNA and lentiviral transduction
For the amplification of APOPT1 cDNA, total RNA was extracted
from HeLa and HEK293T cells using the TRIzol Plus RNA Purifica-
tion System (Invitrogen-ThermoFisher Scientific) and retrotran-
scribed with the Omniscript RT kit (Qiagen). Approximately 200 ng
of cDNA was used as template for the amplification of APOPT1
using specific primers (Table 1). C-terminal HA tags were added by
PCR amplification, and the GFP tag was added by cloning a stop
codon-less APOPT1 cDNA in frame with EGFP already inserted into
pCR2.1. The PCR generated fragments in pCR2.1 TA cloning vector
(Invitrogen) were then cloned into pWPXLd-ires-PuroR and
pWPXLd-ires-HygroR lentiviral expression vectors, modified
versions of pWPXLd (Addgene #12258), by restriction enzyme
digestion with PmeI and BamHI and ligation using T4 DNA ligase.
Lentiviral particles were generated in HEK293T packaging cells
by co-transfection of the target vector with the packaging psPAX2
(Addgene plasmid #12260) and envelope pMD2.G (Addgene
#12259) vectors. Target cells were transduced as described (Perales-
Clemente et al, 2008). Twenty-four hours after transduction, cells
were selected for puromycin or hygromycin resistance.
Primary skin fibroblasts were immortalized by lentiviral trans-
duction of pLOXTtag-iresTK (Addgene #12246).
All the utilized lentiviral vectors were a gift from Didier Trono.
Quantitative PCR
For the quantification of mRNA levels, cDNA was retrotranscribed
from total RNA extracted from mouse tissues or cultured cells (see
above). Specific Gene Expression TaqMan assays (Invitrogen) were
used for each of the transcripts of interest. Expression was calcu-
lated using the ΔΔCt analysis using GAPDH as the reference.
Native and denaturing electrophoresis and Western blot analysis
Samples for blue-native gel electrophoresis (BNGE) were prepared
as described previously (Nijtmans et al, 2002; Wittig et al, 2006).
Native samples were run through pre-cast NativePAGE 3–12%
Bis–Tris gels, while Novex NuPAGE 4–12% Bis–Tris Gels (Life
Technologies) were used for denaturing conditions.
For Western blot, samples were electroblotted to PVDF
membranes and immunodetected using commercial specific anti-
bodies from purchased from Abcam, Proteintech, Atlas Antibodies,
Sigma, Santa Cruz, and Roche (Table 2). Polyclonal antibodies
against APOPT1 were generated against the full-length recombinant
human protein by Proteintech Group (Chicago, IL, USA; Catalog
number: 27300-1-AP) and custom-made by Proteogenix (Schil-
tigheim, France).
Immunodetection signal intensities were quantified using
ImageJ.
Super-resolution fluorescence imaging and analysis
143B cells stably expressing APOPT1-GFP were transfected with dif-
ferent sub-compartment markers: mito-mScarlet (M), COX8A-DsRed
(IM and TOMM20-DsRed (OM), or stained with MitoTracker
CMXRos Red (Invitrogen) for IM + M, cells were then fixed with
3.7% formaldehyde. Coverslips were mounted with ProLong
Diamond (Invitrogen).
Acquisition was performed using a N-SIM microscope system
(Nikon) equipped with a SR Apo TIRF 100× 1.49 N.A. objective
Table 1. Oligonucleotides used for human APOPT1.
Name Sequence
APOPT1 cDNA Fw AATGCTGCCGTGCGCCGC
APOPT1 cDNA Rv TGCTTCCTGTGGAAACCTGG
APOPT1-M1-PmeI-Fw GTTTAAACCATGCTGCCGTGCGCCGCG
APOPT1-M14-PmeI-Fw GTTTAAACCATGGTGGTCTTGCGGGCGG
APOPT1-201-HA-Rv TCAAGCGTAATCTGGAACATCGTATGGGTAGTTGCTCCTCTTCTTTTGTTTC
APOPT1-203-HA-Rv TCAAGCGTAATCTGGAACATCGTATGGGTAATGTTGCTTTCTGACCTTAC
APOPT1-201-GFP-pCR-NdeI-Rv CATATGGTTGCTCCTCTTCTTTTGTTTC
APOPT1-203-GFP-pCR-NdeI-Rv CATATGATGTTGCTTTCTGACCTTAC
ª 2018 The Authors EMBO Molecular Medicine 11: e9582 | 2019 17 of 21
Alba Signes et al APOPT1 protects COX assembly from stress EMBO Molecular Medicine
Published online: December 14, 2018 
and a DU897 Ixon camera (Andor Technologies). 3D-SIM image
stacks were acquired with a Z-distance of 0.15 lm, and all the
raw images were computationally reconstructed using the recon-
struction slice system from NIS-Elements software (Nikon) keep-
ing the same parameters. The co-localization analysis was
performed using Imaris 9.0 XT software (Bitplane Scientific
Software). For each image, threshold was applied in the same
way using automated ROI threshold for the sub-compartments
channel and adjusted in the same range for GFP staining. Pear-
son’s coefficient in the co-localized volume was calculated for
each image.
Statistical analysis
All numerical data are expressed as mean  SEM (standard error).
GraphPad PRISM software v.7.0e was used for the statistical analy-
ses. To evaluate statistical significance of the differences between
experimental groups, one-way ANOVA with Tukey’s multiple
comparisons or two-way ANOVA with Sidak’s multiple comparison
test was used. Unpaired, two-tailed Student’s t-tests were used to
evaluate statistical differences between two experimental condi-
tions. P < 0.05 was considered statistically significant.
Exact P-values and number of animals or biological replicas (n)
for each experiment are indicated in the figure legends. Power anal-
ysis was conducted assuming a significance level of 0.05 and a prob-
ability of detecting the effect of 80%. Animals were randomized to
the different groups based on the appropriate genotype. No animals
were excluded from analysis. No blinding procedure was used. We
assumed normal distribution. No particular method was used to
determine whether the data met assumptions of the statistical
approach.
Expanded View for this article is available online.
Acknowledgements
We are grateful to Dr. Lorenza Ronfani and co-workers from the Core Facility
for Conditional Mutagenesis of the San Raffaele IRCCS (Milan, Italy). We
thank Drs. Sara Vidoni, Marta Luna-Sanchez, Sukru Anil Dogan, and Aurora
Gomez-Duran for their help and advice. Our work was supported by the Core
Grant from the MRC (Grant MC_UU_00015/5); ERC Advanced under Grant
FP7-322424 and NRJ-Institut de France Grant (to M.Z.); Telethon Foundation
Italy Grant GGP15091 (to D.G.); Wellcome Trust Senior Clinical Research
Fellowship 102770/Z/13/Z; and Lister Institute of Preventative Medicine
RG87950 (to JAN).
Table 2. Antibodies used in this study.
Antigen Type Dilutiona Company Catalog number
ACO2 Mouse monoclonal 1:10,000 Abcam 6F12BD9
APOPT1 Rabbit polyclonal 1:1,000 Proteintech 27300-1-AP
AIF Mouse monoclonal 1:1,000 Santa Cruz sc-13116
AK2 Rabbit monoclonal 1:3,000 Abcam ab166901
COX4 Mouse monoclonal 1:3,000 Abcam ab14744
COX5A Mouse monoclonal 1:1,000 Abcam ab110262
COX5B Mouse monoclonal 1:1,000 Abcam ab110263
COX6B Mouse monoclonal 1:1,000 Abcam ab110266
GAPDH Mouse monoclonal 1:5,000 Abcam ab8245
GFP Mouse monoclonal 1:10,000 Abcam ab1218
HA Rat monoclonal 1:1,000 Roche 11 867 431 001
HSP70 Mouse monoclonal 1:1,000 Abcam ab2787
MTCO1 Mouse monoclonal 1:3,000 Abcam ab14705
MTCO2 Mouse monoclonal 1:10,000 Abcam ab110258
MTCO2 Rabbit polyclonal 1:2,000 Abcam ab91317
MTCO3 Mouse monoclonal 1:5,000 Abcam ab110259
NDUFS1 Rabbit polyclonal 1:1,000 Abcam ab102552
PNKD (MR-1S) Rabbit polyclonal 1:1,000 Atlas Antibodies HPA010134
SCO2 Rabbit polyclonal 1:1,000 Proteintech 21223-1-AP
SDHB Mouse monoclonal 1:10,000 Abcam ab14714
SOD2 Mouse monoclonal 1:2,000 Abcam ab16956
BETA-TUBULIN Mouse monoclonal 1:10,000 Sigma T5201
TOM20 Rabbit monoclonal 1:10,000 Abcam ab186734
UBIQUITIN Mouse monoclonal 1:2,000 Invitrogen 13-1600
UQCRC2 Mouse monoclonal 1:2,000 Abcam ab14745
aAll primary antibodies were incubated overnight at 4°C.
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